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Platelets perform a critical role in both physiologic hemostasis and pathologic 
thrombosis, and the production and activation of platelets involves intricate 
regulation of cytoskeletal processes within these cells.  A greater understanding of 
these cytoskeletal processes within platelets will offer the ability to manipulate them 
in hope of mitigating pathologies.  In this dissertation I present a continuum of work 
progressing from the study of neural guidance cues in immune cells to neural 
guidance cues in platelet cytoskeletal function and finally to cytoskeletal alterations 
required for platelet production in thrombopoiesis. 
This work begins with the finding that, contrary to published reports, Slit2 
does not regulate neutrophils directly, but instead acts through Robo4 to blunt 
endothelial hyper-response to cytokine storm. 
These studies led naturally into studies of guidance cues in other 
hematopoietic lineages, specifically platelets.  I present data suggesting that 
Semaphorin 3E (Sema3E) inhibits all stages of platelet activation.  Additionally, 
Sema3E reversibly inhibits platelet function by inactivating Rap1b, which is required 
for activation of llb3 integrin.  In attempts to determine the platelet receptor for 
Sema3E, using mice with a platelet-specific conditional deletion of the Sema3E 
receptor PlexinD1, I determined that PlexinD1 is not necessary for the platelet 
inhibitory activities of Sema3E.  Simultaneously, in an attempt to produce Sema3E 
protein, I determined that effects originally attributed to Sema3E were in fact a result 
of Tween-20 contamination from commercially produced Sema3E formulation, thus 
terminating my studies of Semaphorins in platelets and suggesting the need for 
another look at the previously published reports of Sema3A in platelets. 
The study of cytoskeletal regulation in platelets lent naturally to the study of 
cytoskeletal functions in thrombopoiesis.  Here I show that the proteasome inhibitor 
bortezomib causes thrombocytopenia by blunting platelet production in mice, 
consistent with clinical studies in humans.  Furthermore, bortezomib prevents the 
production of proplatelets from megakaryocytes.  I demonstrate that bortezomib 
treatment elevates both RhoA protein levels and RhoA activation in megakaryocytes 
and that inhibition of RhoA or its downstream kinase ROCK restores proplatelet 
production.  As currently-approved drugs exist that inhibit both RhoA and ROCK, I 
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TARGETING ROBO4-DEPENDENT SLIT SIGNALING 
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SEMAPHORIN EFFECTS ON PLATELET FUNCTION  
ARE CAUSED BY DETERGENT CONTAMINATION 
 
Summary 
 The following chapter pertains to work not intended for publication.  Within 
this chapter I describe the effects of the neural guidance cue, Semaphorin 3E 
(Sema3E), and its ability to reversibly inhibit platelet function both in vitro and in vivo. 
This chapter also details a contamination discovered within the commercially 
produced Sema3E and the detailed process of determining that the original effects 




Platelets play a crucial role normal hemostasis in response to injury, but are 
also instrumental in forming thrombi that precipitate both myocardial infarctions and 
ischemic cerebrovascular accidents1.  Once thought of as simply anucleate particles 
that plug holes in the vasculature, platelets are now known to undergo intricate 
cellular processes, including extensive cytoskeletal rearrangement necessary for the 
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formation of stable thrombi that contribute to endothelial healing and wound repair2.  
In response to vascular injury, platelets interact with collagen, von Willebrand factor 
(vWF) and other components of the subendothelial matrix via specific receptor-
ligand interactions3.  Once the cells adhere, platelet IIb3 integrins undergo a 
conformational change that allows stable adhesion to the extracellular matrix and 
further activates the platelets.  The activated platelets generate thromboxane A2 
(TxA2) and release an array of factors including fibrinogen and adenosine 
diphosphate (ADP) that promote activation of surrounding platelets3.  Activated 
platelets in the area of injury then begin to form aggregates by binding to the 
platelets initially activated by the exposed subendothelial matrix.  These aggregates 
are formed through cross-linking of fibrinogen molecules between platelets, leading 
to formation of a hemostatic plug or thrombus3,4.  
The cytoskeletal changes required for this sequence of events in platelet 
activation are reminiscent of those involved in axon guidance and endothelial cell 
migration during development.  Similarities among these cells beg the question as to 
whether cytoskeletal rearrangements of platelets are regulated by the same 
mechanisms that direct axon guidance and vascular development.  The idea that 
molecules once thought to be primarily involved in directing axon growth are also 
involved in the development and function of other tissues is a rapidly emerging field5-
8.  Each of the four classes of molecules originally thought to function primarily in 
axon guidance (slits, netrins, semaphorins and ephrins) have been implicated in 
vascular and cardiac development and more recently in immune system function6,9.   
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Semaphorins are one of the largest families of conserved guidance cues and 
participate in a plethora of biological processes from neural and cardiovascular 
development to immune cell function5,9-11.  Semaphorins are expressed in many 
tissues, including the vasculature11, and are characterized by the presence of a 
conserved ~500 amino-acid semaphorin (Sema) domain12. They are present in both 
membrane bound and secreted forms and signal primarily through the plexin family 
of receptors.  With the exception of Sema3E and Sema4A, which bind to PlexinD1, 
semaphorins bind to plexins with the help of a neuropilin (NRP1 or NRP2) 
coreceptor12-14. Plexin receptors also possess a sema domain, and plexin-
semaphorin binding occurs through binding of the sema domain on semaphorins to 
the sema domain on their plexin receptors12. 
 In addition to the sema domain, plexins contain a segmented GTPase-
activating protein (GAP) domain and a GTPase binding domain12. Upon binding to 
its specific semaphorin ligand, plexins activate their intrinsic GAP activity, which 
inactivates the small GTPase R-Ras.  Active R-Ras is necessary to maintain 
integrins in an active form; inactivating R-Ras leads to detachment of integrins from 
their ECM substrates15,16.  At the same time, plexins activate the small GTPase 
RhoA, which promotes increased actomyosin contractility12,17. It has also been 
suggested that upon activation, plexins sequester active Rac at the membrane, 
preventing PAK1 phosphorylation and subsequent actin polymerization18,19.  In 
neurons, the combination of these signaling events promotes the collapse of the 
growth cones (Figure 3.1)12.  
 
 
Figure 3.1.  Semaphorin signaling through plexins initiates a number of 
signaling pathways.  Actomyosin contractility is increased through RhoA 
activation by leukemia-associated Rho-GEF (LARG) and by blocking Rac 
signaling through p21-activated kinase (PAK; not shown).  Stimulation of the 
plexin GAP (GTPase-activating protein) activity decreases active R-Ras, 
which limits integrin-mediated attachment. Modified from Kruger et al., Nature 
Reviews, 2005. 
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The importance of cytoskeletal modifications in platelet activation and the 
mechanisms involved in neural guidance cue function suggest that neural guidance 
cues may be very important in regulation of platelet activation. 
 
Results 
Platelet activation and thrombus formation are highly dependent on a series 
of cytoskeletal changes within the platelet.  In order to assess the possibility that 
these processes might be regulated by neural guidance cues, we performed a 
screen to determine the effect of neural guidance cues on platelet spreading.  We 
used ligands from three of the four major guidance cue families (slits, netrins, and 
semaphorins) and assessed their effect on platelet spreading on fibrinogen (Figure 
3.2a-f).  It has previously been reported that Sema3A can inhibit platelet function20; 
our data suggests that multiple members of the semaphorin family but not the slit or 
netrin families can inhibit platelet spreading (Figure 3.2).  Interestingly, our screen 
found that Sema3E was able to inhibit platelet spreading and was at least an order 
of magnitude more potent than the previously published Sema3A.  Furthermore, if 
Sema3E is washed from platelets, they recovered the ability to spread similar to 
untreated platelets. For these reasons, we chose to focus our efforts on exploring 
the role of Sema3E in platelet activation. 
Unlike many of the other semaphorins that require a neuropilin co-receptor, 
Sema3E signals directly through PlexinD114. We found that platelets contain mRNA 
encoding PlexinD1 and that PlexinD1 is highly expressed on the plasma membranes 









Figure 3.2.  Semaphorin family members inhibit platelet spreading. Human 
platelets were pretreated with Slit2 (A), Netrin1 (B), Semaphorin3A (C), vehicle 
(D), or Semaphorin3E (E) for 10 minutes and subsequently adhered to 
immobilized fibrinogen in the presence of thrombin (0.05 U/ml).  After 30 
minutes the cells were stained with alexa 488 phalloidin.  In panel F the 
platelets were treated similarly with the exception that after 10 minutes of 
adherence in the presence of Sema3E, the culture media was replaced with 
semaphorin 3E-deficient media and then the cells were treated with thrombin. 
Arrowheads indicate unspread platelets.  This figure is representative of 4 
independent experiments. Staining=Phalloidin 
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for Sema3E induced collapse, we utilized a heterologous system that does not 
express PlexinD1 at baseline.  CHO-PLA1 cells have been stably transfected with 
both integrin alpha chain 2b (ITGA2B) and integrin beta 3 (ITGB3), the genes that 
comprise the platelet specific integrin IIb321.  When plated on immobilized 
fibrinogen, CHO-PLA1 cells spread similar to platelets and are commonly used to 
study platelet integrin function.   We transfected CHO-PLA1 cells with a plasmid 
containing hPLXND1 or a control plasmid and treated these cells with Sema3E.  
CHO-PLA1 cells that expressed PlexinD1 as assayed by immunofluorescent cell 
staining collapsed in the presence of Sema3E, but CHO-PLA1 cells that were 
negative for PlexinD1 remained spread (Figure 3.3c,d).  These data suggest that 
PlexinD1 is sufficient for the collapsing activity of Sema3E seen in platelets.  The 
expression of both Sema3E and Sema4A – a membrane bound semaphorin that 
also signals exclusively through PlexinD1 – has been reported on the vascular 
endothelium, strongly suggesting that endogenous PlexinD1 signaling occurs in 
vivo
11.  We have confirmed these expression results using reverse transcriptase-
PCR on primary human umbilical vein endothelial cells (HUVEC, data not shown). 
In order to determine where in the platelet activation sequence Sema3E acts, 
we also measured the effects of Sema3E on platelet adhesion and granule 
secretion.  Sema3E inhibited platelet adhesion to immobilized fibrinogen, collagen, 
and laminin, though the effects were most prominent on fibrinogen (Figure 3.4a and 
data not shown).  Two surrogate markers for granule secretion were assayed. First 
we measured the production of soluble RANTES in response to thrombin; RANTES 































Figure 3.3. PlexinD1 is expressed in platelets and is sufficient to mediate 
Sema3E’s collapsing effects on a heterologous cell line.  PlexinD1 mRNA 
transcription relative to GAPDH, PlexinB2 has lower expression by comparison 
(A). Plexin is expressed at the surface of platelets (B).  CHO cells stably 
expressing IIb3 integrin were transiently transfected with PlexinD1 (Green) 
and plated on immobilized fibrinogen in the absence (C) or presence (D) of 
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released upon platelet activation.  Sema3E inhibited the secretion of RANTES in a 
dose-dependent manner (Figure 3.4b).  We also assayed granule release of p-
selectin from the platelet granules to the platelet membrane using flow cytometry for 
membrane bound p-selectin (CD62P).  We found that Sema3E inhibited surface 
expression of CD62P in response to a number of agonists including Thrombin, ADP, 
Convulxin and collagen (Figure 3.4c and data not shown).  In addition to preventing 
platelet adhesion, spreading, and granule secretion, Sema3E also inhibited 
thrombin-induced platelet aggregation (Figure 3.4d), suggesting that Sema3E is 
inhibiting a process central to each of these steps in platelet activation.   
Given that Sema3E inhibits each step of platelet activation, many of which 
rely on the activation of the platelet specific IIb3 integrin, and semaphorins are 
known to inhibit integrin function in neurons and endothelial cells12,13, we examined 
the effect of Sema3E on activation of platelet IIb3 integrin.  Thrombin causes 
platelet IIb3 integrin to undergo a conformational change from an inactive form to 
the active form that binds fibrinogen.  Sema3E treatment of platelets inhibits the 
activation of IIb3 integrin by thrombin, but more impressively, if Sema3E is applied 
after thrombin activation, Sema3E reverses the activation of IIb3 in platelets, thus 
reversing the activation of the platelet (Figure 3.5a). 
Rap1b is a small GTPase in the Ras family that is highly expressed in 
platelets and is necessary for maintaining IIb3 integrin in an active 
conformation22,23.  There have been no studies linking PlexinD1 to Rap1, but 
PlexinD1 has been shown to act as a GTPase activating protein (GAP) towards 





















Figure 3.4. Sema3E inhibits platelet adhesion, granule secretion and 
aggregation.  Platelet adhesion to immobilized fibrinogen in the presence or 
absence of thrombin treated with Sema3E or mock control (A). ELISA for 
RANTES secretion from activated platelets with dose response of Sema3E 
(B).  Surface expression of P-selectin as a marker of granule release in the 
presence or absence of thrombin treated with Sema3E or Mock (Vehicle) 
control (C).  Platelet aggregation in response to thrombin (arrow points) in the 
presence of Sema3E or mock control (D). 
 
 
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Sema3E may be inhibiting IIb3 integrin by activating PlexinD1 which may act as a 
Rap1b GAP, thus inactivating Rap1b and subsequently inactivating IIb3 integrin.  
Platelets were treated with thrombin in the presence or absence of Sema3E and 
active Rap1b was assayed over time using a Rap1b pull down assay that specifically 
recognizes GTP bound (active) Rap1b.  Thrombin caused a predictable increase in 
GTP-bound Rap1b, and Sema3E inhibited this activation, suggesting that this may 
be the mechanism for Sema3E’s inhibition of IIb3 integrin and platelet activation 
(Figure 3.5b).  To confirm these results, we tested a Rap1b specific inhibitor, GGTI-
298, for it’s ability to inhibit platelet function.  GGTI-298 was able to inhibit both 
platelet spreading and IIb3 integrin activation similar to Sema3E (Figure 3.5c,d). 
Sema3Es potent ability to inhibit platelets in vitro suggested that it might be 
able to inhibit platelet function in vivo.  In order to test this hypothesis, we utilized a 
ferric chloride (FeCl3) thrombosis model.  Localized administration of ferric chloride 
to the carotid artery causes local endothelial damage and subsequent platelet 
activation and thrombosis.  Ferric chloride was administered to the right proximal 
carotid artery of mice and Doppler ultrasound was used to measure blood flow 
through the artery distal to the injury.  Using 2.4% FeCl3, we reproducibly induced 
complete occlusion of the carotid artery; however, when Sema3E was administered 
to the mice IV two minutes prior to FeCl3 treatment of the carotid artery, this 
occlusion was almost completely inhibited.  Time to occlusion was increased over 
three fold with Sema3E treatment (Figure 3.6a).  Additionally, studies using in vivo 
fluorescence microscopy confirmed that Sema3E could inhibit the activation of 




















































Figure 3.5. Sema3E inhibits IIb3 integrin by inhibiting Rap1b activation. 
Sema3E is able to prevent and reverse binding of activation specific IIb3 
integrin antibody Pac1 (A). Rap1 inhibitor GGTI-298 inhibits Pac1 binding 
(B).  Sema3E inhibits the activation of Rap1b by reducing GTP-Rap1b (C). 
Platelet spreading in response to DMSO control (D) or Rap1 inhibitor 









Figure 3.6. Sema3E inhibits in vivo thrombosis and in vivo platelet 
activation.  Sema3E inhibits ferric chloride induced carotid artery 
thrombosis similar to a known antithrombotic, heparin (A).  Sema3E inhibits 
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          The culmination of these data introduce a neural guidance cue with potent 
anti-platelet activity, working though known platelet specific mechanisms, that is both 
reversible and active in an in vivo model of thrombosis, thus suggesting an ideal 
therapeutic candidate.  In order to solidify these results it became imperative that we 
conclusively establish the receptor for Sema3E and produce Sema3E in our own 
hands to ensure the phenotype is specific and in no way attributable to superfluous 
elements of a commercially produced reagent. 
PlexinD1 is sufficient for the collapsing effects of Sema3E in a heterologous 
cell system, but it is unclear if PlexinD1 is necessary for Sema3E’s effect in platelets.  
To address this question, we created mice deficient in PlexinD1 exclusively in the 
megakaryocyte and platelet lineage.  Because PLXND1 deficient mice are lethal by 
postnatal day 1, we specifically targeted PLXND1 knockout to platelets by use of 
platelet-specific Cre recombinase (PLXND1flox/flox;PF4-Cre, denoted PlxnD1PltKO). 
PLXND1PltKO mice were viable and survived till weaning in expected Mendelian ratios 
suggesting no lethality in the platelet specific knockout.  If Plexin were necessary for 
Sema3E’s effect on platelets, PlxnD1PltKO platelets would not be inhibited by 
Sema3E.  We tested the effects of Sema3E in platelets isolated from PlxnD1PltKO 
mice by assaying platelet spreading, granule release, and integrin activation.  
Surprisingly, Sema3E was able to collapse PlxnD1PltKO platelets, inhibit granule 
release, and inhibit activation of IIb3 integrin (Data not shown and Figure 3.7a).  
Furthermore, platelets isolated from PlxnD1PltKO mice or wild type littermate controls 
showed no difference in dose-dependent response to Sema3E (Figure 3.7a).  
Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was used to 
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determine PlexinD1 transcription in each mouse genotype and confirmed that 
PlexinD1 levels were markedly decreased in PlxnD1PltKO platelets (Figure 3.7b).  
These data suggest that PlexinD1 is not necessary for Sema3E’s effect on platelets, 
which is contrary to the current view of semaphorin-plexin biology14. 
Despite these surprising and confusing results, we prepared to treat 
PlxnD1PltKO mice with Sema3E in the ferric chloride-induced thrombosis model.  
These studies would require large quantities of Sema3E, so we constructed a 
plasmid to express human Sema3E for purification from HEK 293T cells.  A 
SEMA3E expressing plasmid was obtained from David Ginty14 and was modified to 
contain an eight histamine residue tag and to be highly expressed in a secreted form 
from HEK 293T cells (Figure 3.8a).  Sema3E was purified from the conditioned 
media of 8his-SEMA3E transfected HEK-293T cells.  This conditioned media was 
then concentrated using size exclusion filters and the His-Sema3E was purified 
using nickel purification followed by size exclusion chromatography.  His-Sema3E 
along with a control isolated in the same fashion from cells transfected with an 
empty plasmid lacking the SEMA3E gene (mock) were then tested for platelet 
inhibitory activity.  Surprisingly, both His-Sema3E and mock treatment inhibited 
platelet activation as measured by surface P-selectin expression and activation of 
IIb3 integrin (data not shown and Figure 3.8b).  This result was unexpected and led 
us to suspect contamination in the His-Sema3E and mock preparations.  Size 
exclusion during purification, however, should have removed most proteins and 
small molecules from the His-Sema3E.  Retrospective analysis of our His-Sema3E 





























Figure 3.7. Platelets from PlxnD1flox/flox;Pf4Cre mice are PlexinD1 deficient 
but still respond to Sema3E.  Sema3E inhibits platelets isolated from 
PlxnD1PltKO mice similarly to platelets isolated from wild type mice (A). 
PlxnD1PltKO platelets have markedly reduced expression of PlexinD1 
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presence of the detergent Tween-20 in the wash buffers for protein purification.  
Original preparations of His-Sema3E that did not utilize Tween-20 showed no 
platelet inhibitory activity.  The Sema3E used in our initial experiments was 
purchased from R&D Systems and was reported to contain 0.05% Tween-20.  
These data led us to hypothesize that Tween-20 was necessary for Sema3E to 
maintain proper protein folding and activity.  Adding Tween-20 to the wash buffers 
during our His-Sema3E preparations reestablished platelet inhibitory activity.  These 
observations led us to ask if it was possible that Tween-20 was causing the platelet 
inhibitory actions we were observing with His-Sema3E. 
Tween-20 was tested in platelet collapsing assays, and we found that Tween-
20 was able to collapse platelets at concentrations as low as 0.002%, near the 
concentration anticipated in R&D Systems produced Sema3E diluted into platelets 
with growth media (Figure 3.8c). Tween-20 has been reported to form micelles that 
appear between 35 and 200kDa depending on the method of analysis24,25.  Using 
size exclusion chromatography, we determined that Tween-20 was enhanced in 
fractions equivalent to ~180kDa proteins, the precise molecular weight of dimerized 
His-Sema3E (Figure 3.9a-c).  These data implied that despite our efforts to remove 
the detergent along with any other contaminants from the His-Sema3E, we were 
enhancing the Tween-20 concentration, suggesting that we may be producing 
functional His-Sema3E without the use of Tween-20 but that His-Sema3E does not 
inhibit platelet activity.  Sema3E is known to inhibit spreading of endothelial cells, 
which naturally express PlexinD1 26.  We tested His-Sema3E, purified with and 








































Figure 3.8. Tween-20 but not His-Sema3E inhibits platelet activation. 
Construction of His-tagged human Sema3E to be expressed in HEK 293T 
cells (A).  Both His-Sema3E and Mock control inhibit activation of platelet IIb3 
integrin (B).  Tween-20 is able to collapse platelets similar to previous results 












Figure 3.9. Tween-20 micelles are purified with His-Sema3E in size exclusion 
chromatography (SEC).  Purified His-Sema3E in SEC migrates as a dimer and 
is eluted at approximately fraction 54.  Protein aggregates are seen in fractions 
34-42 (A).  Mock preparation that should contain no protein demonstrates 
something eluting at the same fraction as dimerized His-Sema3E (B).  0.05% 
Tween-20 on SEC elutes at the same fraction as dimerized His-Sema3E (C). 
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express PlexinD1.  We found that His-Sema3E but not mock preparations could 
collapse HUVEC regardless of the presence of Tween-20, but only the preparations 
containing Tween-20 (His-Sema3E or mock) could collapse platelets (Figure 3.10).  
To further test these findings, we used antibody depletion to remove Sema3E from 
R&D Systems protein preparations.  R&D Systems Sema3E that had been depleted 
using antibodies directed against Sema3E continued to inhibit platelet spreading and 
activation of IIb3 integrin, indicating that Sema3E was not responsible for the 
platelet inhibitory activities observed in previously described experiments, and that 
the platelet inhibitory activity lay with the Tween-20 in the buffer of the Sema3E 
(Figure 3.11).   
 
Discussion 
 Platelets have long been a model for the study of axon biology due to their 
lack of nuclei and ease of procurement, and the cytoskeletal rearrangements that 
take place in platelet spreading share many of the same mechanisms as those in 
axon guidance.  Specifically, both cells rely on integrin activation and actin dynamics 
to change cell shape in order to function.  These similarities led us to hypothesize 
that neural guidance cues could inform us about platelet biology and potentially offer 
insights into anti-platelet therapies.  The expression of PlexinD1 on platelet 
membranes, a cell with limited ability to regulate gene expression, was strong 
evidence in favor of this hypothesis, suggesting that there must be a biological 
purpose for this receptor.  Additionally, other neural guidance cues, including 
Semaphorin 4D and ephrins, have been characterized in platelets and shown to  

Figure 3.10. Platelet collapse activity is correlated with presence of Tween-
20, not with His-Sema3E.  Platelets and HUVEC treated with His-Sema3E 
or mock purified in the presence of Tween-20 (A). Platelets and HUVEC 







































































Figure 3.11. Depleted Sema3E inhibits platelets but not HUVEC.  Western 
Blot showing Sema3E was depleted using an anti-Sema3E antibody (A). IIb3 
integrin activation with depleted Sema3E (B).  Quantification of deleted 
Sema3E, arrowhead denotes expected Sema3E dimer (C).  Platelet and 
HUVEC spreading with depleted or undepleted Sema3E (D). 
 
 
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modulate platelet cytoskeletons much like they modulate the developing axon 
structure27,28.  Additionally, there have been reports that Semaphorin 3A inhibits 
platelet function similar to our results with Semaphorin 3E20.  These data strongly 
supported our hypothesis that Sema3E, signaling through PlexinD1, could be an 
endogenous mechanism to inhibit platelet activation and promote platelet 
quiescence.  However, vigilant performance of strict, arduous controls and careful, 
incisive data analysis led us to conclude that Sema3E’s platelet inhibitory activity 
was due to contamination from a detergent in buffer. 
 Given our results, the Semaphorin 3A report, and indeed all reports 
characterizing a compound with anti-platelet activity, need to be carefully re-
evaluated.  After our discovery that Tween-20 inhibited platelet function, we did a 
second, more exhaustive screen on the commercially available Semaphorins and 
their effects on platelet activation.  We found a perfect correlation between 
semaphorins that were produced using Tween-20 with their ability to inhibit platelets 
(data not shown).  The concentration of Tween-20 reported by the manufacturer was 
always 0.05%, which when diluted into experimental conditions would usually result 
in a concentration of 0.001%-0.005% Tween-20.  This concentration is below the 
critical concentration required to form micelles (CMC=0.007%)24; however, our 
independent mass spectrometry studies suggested that Tween-20 concentrations in 
the commercial protein preps were as high as 25 times that reported on certificates 
of analysis provided by R&D systems.  These discrepancies are likely due to size-
based purification within the commercial preparation process, probably either 
molecular weight cut off filters or size exclusion chromatography.  In either case, 
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0.05% Tween-20 is greater than the CMC for Tween-20, which would cause the 
Tween-20 to segregate with the semaphorin, thus concentrating it in a similar 
fashion.  
 These data have wide reaching implications into the field of platelet biology, 
especially on published work related to guidance cue inhibition of platelets, as we 
have demonstrated the sensitivity of this primary cell type to detergents and other 
materials commonly used in research.  Future studies into platelet inhibition for the 
purposes of antithrombotic therapy will require increased scrutiny to ensure that 
antithrombotic effects are indeed specific and in no way attributable to the sensitivity 
of the platelet.  Our data, which identified the specific contaminant and demonstrated 
the sufficiency of that contaminant to cause a multitude of reversible anti-platelet 
effects have led us to discontinue further research into the effect of neural guidance 
cues on platelet function for the time being. 
 
Methods 
Human platelet isolation.  Human blood was drawn into acid-citrate-dextrose 
(ACD) (7 ml ACD/42 ml of blood) and was centrifuged (200g for 20 min) to obtain 
platelet-rich plasma (PRP). PRP was recentrifuged (500g for 20 min) in the presence 
of 100 nM prostacyclin (PGE-1). The supernatant was discarded and 50 ml of 
Pipes/saline/glucose (PSG; 5 mM Pipes, 145 mM NaCl, 4 mM KCl, 50mM Na2HPO4, 
1 mM MgCl2–6 H2O, and 5.5 mM glucose), containing 100 nM of PGE-1, was used 
to resuspend the platelet pellet. The platelet suspension was centrifuged (500 g for 
20 min), the supernatant was discarded, and the platelet pellet was resuspended in 
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Ca2+- and Mg2+-free HBSS (Invitrogen). All studies are approved by the University of 
Utah's Institutional Review Board (IRB). The cells were resuspended in medium 199 
(M199, Invitrogen) at 37°C for each experiment. Where indicated, the washed 
platelets were pretreated with Semaphorin3E (R&D Systems) (10 μg/ml) or vehicle 
(M199+0.1% human serum albumin) for 10 minutes at room temperature (RT) prior 
to start of each study. 
Mouse platelet isolation.  Mouse blood was drawn via carotid artery cannula 
into ACD (150μl/1ml blood)  Blood/ACD was then diluted 1:2 with PSG and 
centrifuged (200g for 10 min) to obtain PRP. PRP was diluted again 1:2 with PSG 
and was recentrifuged (500g for 7 min) in the presence of 100 nM PGE-1. The 
supernatant was discarded and 2 ml of PSG containing 100 nM of PGE-1 was used 
to resuspend the platelet pellet. The platelet suspension was centrifuged (500 g for 7 
min), the supernatant was discarded, and the platelet pellet was resuspended in 
M199. 
Platelet adhesion and spreading.  8-well borosilicate chamber slides (Nalge 
Nunc International, Rochester, NY) were coated with 100ug/ml fibrinogen, 50μg/ml 
collagen, or 50μg/ml laminin overnight at 4° followed by blocking with 0.5% human 
serum albumin for 30 minutes at 37°.  Chamber slides were washed 3x with HBSS.  
Platelets (2 x 107) in M199 were incubated with 10 g/mL hSema3A/Fc, hSema3E, 
mSema3E/Fc mSema3F/Fc, or hIgG (R&D Systems) for 10 minutes at room 
temperature, and then they were placed on the coated chamber slides for 30 
minutes at 37°, 5% CO2 in the presence or absence of 0.05U/ml Thrombin or 
20μg/ml ADP. Platelets were fixed for 20 minutes with 2% PFA and washed three 
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times with HBSS.  Morphologic study of adhered platelets was performed by staining 
platelets with Alexa Fluor 488-phalloidin and 544-WGA followed by imaging using 
confocal microscopy.  Adhesion assays were performed by counting platelets in 5 
high powered fields.   For wash experiments, Sema3E treated platelets were seeded 
on fibrinogen coated chamber slides and allowed to spread for 10 minutes.  Then 
Sema3E containing media was removed, cells were washed once with M199, and 
M199 containing 0.05U/ml thrombin was added to platelets.  Platelets were then 
allowed to spread for 30 minutes. 
Platelet contraction. Platelet contraction studies were performed like platelet 
spreading studies with the exception that platelets were allowed to adhere in the 
presence of thrombin for 10 minutes before Sema3E was added.  Platelets were 
then allowed to adhere/contract for 20 more minutes at 37°. 
Immunocytochemistry.  CHO-PLA1 cells transiently transfected with 
hPlexinD1, or platelets were allowed to spread on fibrinogen coated chamber slides 
as above.  Fixed cells were blocked with 1% bovine serum albumin (BSA) and 
stained with Alexa Fluor 544-Phalloidin (Molecular Probes, Eugene, OR) and goat 
anti-plexinD1 (R&D systems, Minneapolis, MN) for 1 hour at room temperature (RT) 
followed by Alexa Fluor 488 donkey anti-goat 488-IgG (Molecular Probes, Eugene, 
OR) for 1 hour at RT.  Cells were imaged using confocal microscopy. 
RANTES ELISA.  Washed human platelets were treated with specified 
concentrations of Sema3E for 10 minutes at RT followed by 0.05U/ml Thrombin for 
10 minutes.  Platelets were then centrifuged at 500g for 10 minutes, and 
supernatants were removed and used for RANTES ELISA according to the 
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manufacturer’s protocol (human Rantes DuoSet Elisa, R&D systems, Minneapolis, 
MN). 
Granular secretion as detected by membrane expression of P-selectin.  
Washed human platelets were treated with Sema3E or vehicle as described above 
followed by various platelet agonists for 15 minutes in the presence of FITC-CD62P 
antibody.  Membrane P-selectin expression was immediately monitored using flow 
cytometry. 
Platelet aggregation.  Platelet aggregation was monitored using a platelet 
aggregometer at 37°C with a stirring rate of 1000 rpm.  Sema3E or vehicle treated 
platelets were suspended in M199 at 109/ml and aggregation was initiated by 
addition of 0.05U/ml thrombin. 
Activation of IIb3 by various agonists.  Activation state of IIb3 was 
monitored by binding of ligand-mimetic antibodies.  106 platelets in M199 were 
preincubated with Sema3E for 10 minutes, followed by incubation with agonists and 
FITC-conjugated PAC-1 (BD Biosciences, Franklin Lakes, NJ) for human platelets or 
PE-JonA (Emfret, Eibelstadt, Germany) for mouse platelets for 15 minutes at room 
temperature. Then, platelets were analyzed immediately by flow cytometry. 
Purification of His-Sema3E. The NaCl and Tween-20 were added to the 
conditioned media from transient transfection of HEK293T or stable transfection of 
HEK293 FS with hSema3E 8xHis (KARFAR) to the final concentration of 0.5M NaCl 
and 0.05% Tween-20 before loaded to HisTrapTM FF (GE Healthcare Lifescience) 
The column was washed with 5 column volume of 500mM NaCl, 0.54mM KCl, 
0.86mM Na2HPO4, 0.29mM KH2PO4, 75mM imidazole, and 0.05% Tween-20 at a 
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flowrate of 1ml/min using Biologic DuoFlow (Bio-Rad). Sema3E was eluted from 
HisTrapTM FF with the gradient of 75-300mM imidazole over 10ml of buffer described 
above. The Eluted protein was dialyzed with PBS (137mM NaCl, 2.7mM KCl, 4.3mM 
Na2HPO4, 1.47mM KH2PO4) and reduced to 1ml using Amicon Ultra
TM 30K MWCO 
(molecular weight cut off). The eluted protein was further purified with sizing column 
SuperdexTM200 10/300GL (GE Healthcare Lifescience) equilibrated with 500mM 
NaCl, 0.54mM KCl, 0.86mM Na2HPO4, 0.29mM KH2PO4. The Sema3E fractions 
were identified by SDS-PAGE  with reduce and nonreduced condition and 
westernblot with anti Sema3E antibody (R&D System). 
Ferric chloride thrombosis model.  Mice were anesthetized with 
intraperitoneal injection of Avertin (0.3ml of 2.5%) and anesthesia was maintained by 
using inhalation of 2% isoflurane in an isoflurane vaporizer. The skin on top of the 
throat is removed and the fascia bluntly dissected to isolate the left jugular vein.  A 
cannula is then inserted into and immobilized to the left jugular vein for 
administration of Sema3E or saline.  The right common carotid artery was then 
exposed.  Carotid blood flow was monitored using ultrasound biomicroscopy (UBS, 
Visualsonic Vevo 660) with a 40 MHz transducer and image-guided 23 MHz spectral 
pulsed-wave (PW) Doppler. Heart rate, blood flow velocities, and blood flow volumes 
were determined from pulsed Doppler waveforms. During scanning, mouse body 
temperature was maintained within normal range.  Following baseline carotid blood 
flow readings, mice were injected with 200μl of specified control or inhibitor 2 
minutes prior to FeCl3 treatment.  Thrombosis was then induced by applying 2 
pieces of filter paper (1x2 mm) saturated with various concentrations of FeCl3.  The 
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pieces of filter paper were placed on opposite sides of the carotid artery in contact 
with the adventitial surface of the artery.  The FeCl3 saturated filter paper was 
removed after 3 minutes and the area was washed 3x with 1ml saline irrigation.  
Blood flow was then monitored every minute from 5-15 minutes, then at 5-minute 
intervals until 30 minutes after FeCl3 application. 
Intravital fluorescence microscopy.  Antibodies to murine CD41 were labeled 
with Alexa Fluor-660 or -647 using the Alexa Fluor Protein Labeling kit (Molecular 
Probes, Eugene, OR) in accordance with the manufacturer's instructions.  Mice were 
anesthetized with intraperitoneal injection of 125 mg/kg ketamine, 12.5 mg/kg 
xylazine, and 250 g/kg atropine sulfate.  Anesthesia was maintained with 5 mg/kg 
pentobarbital as required through a jugular vein cannula. The cremaster muscle was 
exteriorized, connective tissue was removed, and an incision was made to allow the 
muscle to be affixed as a single sheet over a glass slide. During preparation and 
throughout the experiment the muscle preparation was hydrated with buffer (135 mM 
NaCl, 4.7 mM KCl, 2.7 mM CaCl2, 18 mM NaHCO3, pH 7.4).
  Labeled anti-CD41 
antibody (0.1 g/g bodyweight) was infused through the jugular cannula 10 minutes 
before beginning induction of the first thrombus.  Between 1 and 3 arterioles were 
visible in each cremaster muscle preparation.  Arterioles with undisrupted flow were 
chosen (estimated shear rate between 800 and 1600 s–1) and a number of thrombi 
were studied tracking up each vessel against the direction of blood flow.  Endothelial 
injury was induced using a pulsed nitrogen dye laser at 440 nm that was focused 
onto the blood vessel wall through the microscope optics.  Widefield fluorescence 
(660 nm excitation wavelength, 60 ms) and brightfield (40 ms) images were collected 
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alternately for up to 3 minutes after injury formation. Thrombi were visualized using 
an Olympus AX-70 fluorescence microscope (Olympus, Melville, NY) with a 60x 
water immersion objective lens (numeric aperture 0.9) and recorded using a Cooke 
SensiCam digital camera (Cooke, Auburn Hills, MI).  Images were taken in rapid-
repeating sequence to visualize platelets (excitation wavelength 660 nm, 20 ms) and 
fibrin (excitation wavelength 488 nm, 15 ms) followed by a brightfield image (20 ms).  
Data were collected and analyzed using the SlideBook imaging software (Intelligent 
Imaging Innovations, Denver, CO), and thrombus area and integrated thrombus 
fluorescence were measured over time. 
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PROTEASOMAL INHIBITION CAUSES THROMBOCYTOPENIA 
THROUGH HYPERACTIVATION OF RHOA 
 
Introduction 
 Thrombocytopenia, or low platelet counts, is often a complication of many 
other medical conditions, and results in a dangerous situation in which a person has 
an inability to manage bleeding adequately. The causes of thrombocytopenia are 
multifactorial, ranging from autoimmune diseases (e.g., immune thrombycytopenic 
purpura) to chemotherapy, major trauma, and surgery.  However, the physiologic 
response to any thrombocytopenia is the increased production of new platelets from 
megakaryocyte progenitors in the bone marrow.  Megakaryocytes are rare, polyploid 
myeloid cells that arise from hematopoietic stem cells and are the precursor cells 
that eventually differentiate into platelets1.  The production of these anucleate 
platelets marks the final stage of megakaryocyte development; an intricate 
reorganization of the cytoskeleton eventually results in the production of thousands 
of platelets from a single megakaryocyte in a process termed thrombopoiesis2,3.   
 Thrombopoiesis begins with cellular enlargement along with DNA replication 
through multiple rounds of endomitosis.  The megakaryocyte increases its cytosolic 
content, including ribosomes and other organelles, and replicates its DNA.  
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However, unlike typical mitosis, endomitosis is arrested during anaphase B when the 
mitotic spindles fail to separate and cytokinesis is bypassed.  The megakaryocyte 
goes through many rounds of endomitosis until it reaches a size of nearly 100μm 
and has a DNA content ranging from 4N to 128N2.  Among the enriched cytoplasmic 
contents are proteins necessary for platelet function, including vWF, P-selectin, and 
llb3 integrin; the megakaryocyte packages these proteins appropriately into 
granules or the membrane.  In addition to DNA and cytoplasmic structures, the 
megakaryocyte will also develop an expansive membrane network termed the 
Demarcation Membrane System (DMS).  This membrane network is connected to 
the plasma membrane and serves as a membrane reserve for production of 
proplatelets, the immediate precursor to platelets. 
 Proplatelet formation initiates with the process of pseudopodial elongation 
from the large polyploid megakaryocyte.  These pseudopods elongate and branch to 
form many proplatelet-like extensions from the megakaryocyte until the entire 
cytoplasmic content of the megakaryocyte is involved in an extensive network of 
(Figure 4.1).  At this point, the multilobulated nucleus is extruded from the proplatelet 
network and degraded.  Though the exact events that precipitate the release of 
individual platelets are still unknown, it is thought that these proplatelets invade the 
venous sinusoids of the bone marrow, where blood flow shear stress causes 
individual or pairs of platelets to be released from the proplatelet network into the 
circulation3.  It is unclear exactly how much time is required in vivo for 
thrombopoiesis, from cellular expansion to the release of proplatelets into the 
circulation, but in vitro systems that mimic this process require 13-17 days3. 

Figure 4.1. “Overview of megakaryocyte production of platelets. As 
megakaryocytes transition from immature cells (A) to released platelets (E), a 
systematic series of events occurs. (B) The cells first undergo nuclear 
endomitosis, organelle synthesis, and dramatic cytoplasmic maturation and 
expansion, while a microtubule array, emanating from centrosomes, is 
established. (C) Prior to the onset of proplatelet formation, centrosomes 
disassemble and microtubules translocate to the cell cortex. Proplatelet formation 
commences with the development of thick pseudopods. (D) Sliding of overlapping 
microtubules drives proplatelet elongation as organelles are tracked into 
proplatelet ends, where nascent platelets assemble. Proplatelet formation 
continues to expand throughout the cell while bending and branching amplify 
existing proplatelet ends. (E) The entire megakaryocyte cytoplasm is converted 
into a mass of proplatelets, which are released from the cell. The nucleus is 
eventually extruded from the mass of proplatelets, and individual platelets are 
released from proplatelet ends.” -Adapted from Patel SR, Hartwig JH, and Italiano 
JE, Journal of Clinical Investigation, 2005. 
 
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          The entire process of thrombopoiesis, including differentiation of 
hematopoietic stem cells into immature megakaryocytes, is dependent on 
thrombopoietin4.  Thrombopoietin is constitutively produced in the liver and bone 
marrow stroma and released into the circulation at relatively constant levels 
regardless of platelet count.  It binds primarily to the thrombopoietin receptor c-Mpl, 
expressed on platelets, megakaryocytes and hematopoietic stem cells.   Platelet 
binding of thrombopoietin acts as a sink, soaking up the thrombopoiesis-inducing 
cytokine and preventing it from reaching stem cells or megakaryocytes.  When 
bleeding occurs or platelets are otherwise depleted, more thrombopoietin is 
available to bind to hematopoietic stem cells and megakaryocytes in the bone 
marrow, thus spurring platelet production for a return to normal platelet numbers4.  
Proper regulation of thrombopoeisis and continued production of platelets is 
essential for hemostasis.  Platelets have a lifespan of approximately 10 days and 
normal platelet counts in humans are 150x109 to 400x109/liter4.  Maintaining such 
high numbers of such a short-lived cell means that it would only take 2 to 3 days of 
halted platelet production for a person to fall into thrombocytopenia.  One common 
mechanism of thrombocytopenia is chemotherapy treatment.  Chemotherapy drugs 
frequently cause thrombocytopenia in patients, which may result in bleeding or 
potentially a reduction in chemotherapy dosing in order to avoid thrombocytopenia5.  
Thrombocytopenia of chemotherapy is often attributed to cytotoxic effects of the cell 
cycle-active agents on megakaryocytes and hematopoietic stem cells6.  
Megakaryocytes that are no longer going through the cell cycle can still produce 
platelets, but megakaryocyte differentiation often takes many days following 
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chemotherapy cessation. Therefore, delayed but prolonged periods of 
thrombocytopenia can be expected following treatments7.  
 Bortezomib, a chemotherapeutic primarily used in the treatment of multiple 
myeloma, also causes thrombocytopenia, but with kinetics much different from other 
chemotherapeutics8-10.  Bortezomib causes thrombocytopenia within a few days of 
therapy initiation, but the thrombocytopenia resolves within 2-3 days following 
completion of the treatment.  Moreover, platelet numbers actually rise above their 
pretherapy levels after completion of the treatment, suggesting a very different 
mechanism of thrombocytopenia from the cell cycle inhibition of other 
chemotherapeutics. 
 Bortezomib is the first approved drug in its class and its mechanism of action 
is through reversible yet specific inhibition of the chymotryptic activity of the 
proteasome10.  The proteasome is a 2.5MDa complex of at least 66 proteins 
organized into a 19S regulatory particle and a 20S core particle whose primary 
function in the cell is to degrade proteins that are either misfolded or no longer 
needed11.  The proteasome degrades proteins into 7-8 amino acid peptides through 
enzymatic digestive actions similar to those of trypsin, chymotrypsin, and caspases.  
These amino acids can then be further broken down and recycled for new protein 
synthesis.  Misfolded or short-lived proteins are targeted to the proteasome through 
the actions of a pathway known as the ubiquitin-proteasome pathway, by which a 
series of proteins termed ubiquitin ligases covalently link multiple monomers of 
ubiquitin to the protein to be degraded.  This poly-ubiquitin chain is then recognized 
by the proteasome regulatory subunit and the protein is targeted for destruction12.  
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 Very little is known about the specific functions of the ubiquitin-proteasome 
pathway in megakaryocytes and platelets, though the presence of proteasomal 
function in megakaryocytes and platelets suggests that we can extrapolate what we 
know of the proteasome in other cells13.  A few major platelet-specific molecules are 
regulated at least in part by the proteasome, including pro-llb integrin and the 
thrombopoietin receptor, c-Mpl14,15.  Failure to degrade either of these proteins is 
unlikely to explain the thrombocytopenia associated with bortezomib therapy 
because both are known to be upregulated during thrombopoiesis1.   
 The kinetics of bortezomib-induced thrombocytopenia suggest that inhibition 
of the proteasome may be temporarily stalling thrombopoiesis.  This temporary stall 
in platelet production in the absence of major cytotoxicity to the megakaryocytes and 
hematopoietic stem cells primes the system for increased circulating thrombopoietin 
levels, which then drastically increase platelet production as soon as bortezomib is 
withdrawn7.  This pattern of rapid therapy induced thrombocytopenia followed by 
rapid platelet recovery following treatment cycles is unique to bortezomib and thus 
offers a unique opportunity to determine the role of the proteasome in 
thrombopoiesis.  Better understanding of this process will both advance our 
understanding of mechanisms regulating thrombopoiesis and provide potential 
therapeutic targets for regulation of platelet production. 
 
Results 
 In the clinic, patients treated with bortezomib rapidly develop 
thrombocytopenia within 4 days of initiation of treatment7.  We first aimed to 
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determine if mice were susceptible to the same kinetics of thrombocytopenia 
following bortezomib treatment.  Mice were administered a single dose of 2mg/kg 
body weight of bortezomib and platelet counts were followed for 6 days.  We 
observed an early onset thrombocytopenia beginning within 24 hours of treatment 
that rapidly recovered by 72 hours (Figure 4.2a).  The thrombocytopenia temporally 
correlated with proteasomal inhibition in circulating platelets suggesting that 
proteasomal inhibition was responsible for the kinetics of the thrombocytopenia 
(Figure 4.2b).  Thrombocytopenia is primarily caused by one of two mechanisms: 
reduced platelet production or increased platelet destruction.  To determine which 
mechanism was at work in bortezomib-induced thrombocytopenia, we injected 
platelet-specific antibodies IV along with bortezomib and monitored total platelet 
numbers and the percent of platelets bound to the antibody.  Because free 
circulating antibody of non-host origin will be cleared rapidly, only platelets present in 
the circulation at the time of injection will be labeled.  We determined that platelets 
from mice treated with bortezomib had a half life of 70.5hrs (95% C.I.=64-77hrs), 
nearly identical to mice treated with DMSO control (64.7hrs, 95% C.I.= 59-70hrs 
Figure 4.2c); notably, these platelet half-lives are very similar to those reported by 
others16.  Moreover, the unlabeled platelet population indicated that platelet 
production in bortezomib treated mice is markedly reduced when compared with 
control mice suggesting a defect of platelet production rather than elevated platelet 
destruction (Figure 4.2d). 
Previous studies have suggested that bortezomib may increase platelet 












































































































Figure 4.2.  Bortezomib-induced thrombocytopenia is due to reduced platelet 
production rather than increased platelet destruction.  Bortezomib causes rapid 
onset-rapid recovery thrombocytopenia in mice (A).  Proteasome activity is 
inhibited after in vivo bortezomib treatment (B).  Platelet half-life is unchanged in 
bortezomib treated mice (C).  Platelet production is reduced in bortezomib treated 
mice (D). 
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sequestration in tissues17.  To ensure destruction or sequestration was not 
contributing to bortezomib-induced thrombocytopenia, we isolated platelets from 
mice treated with bortezomib or DMSO control and assessed their response to 
activation.  We found no difference in activation between bortezomib and DMSO-
treated platelets by either granule release and surface presentation of P-selectin or 
llb3 integrin activation in response to multiple agonists (Figure 4.3a-b).  We also 
tested the activation of human platelets in response to agonists from three major 
signaling pathways – thrombin, ADP, and thromboxane – after bortezomib treatment 
in vitro.  We found no difference in surface P-selectin expression or activation of 
llb3 integrin in human platelets treated with bortezomib compared to DMSO control 
(Figures 4.4a,b). To confirm that we were adequately inhibiting of the proteasome, 
we measured levels of polyubiquitinated proteins in the treated platelets; we found 
that the proteasome was indeed inhibited by bortezomib, resulting in a subsequent 
buildup of polyubiquitinated proteins (Figure 4.5a,b).  To further test platelet function, 
we also assayed the effect of bortezomib on platelet spreading on fibrinogen in the 
presence or absence of thrombin; bortezomib had no effect on platelet spreading on 
fibrinogen (Figure 4.5c). These data suggest that bortezomib-treated platelets are 
not hyperactive ex vivo in mice or humans and are in agreement with published 
studies reporting that patients on bortezomib are less likely to develop 
thromboembolic events than patients on other chemotherapeutics18. Furthermore, 
these data suggest that bortezomib has no effect on markers of platelet activation 































































































































































Figure 4.3.   Murine platelet activation from bortezomib treated mice.  Platelet 
granule secretion as measured by P-selectin translocation to the membrane is 
unaltered in platelets from bortezomib treated mice (A).  Platelet llb3 integrin 
activation as measured by binding of ligand-mimetic antibody JonA is unaltered 




























































































































Figure 4.4.  Human platelet activation. Platelet granule secretion as measured 
by P-selectin translocation to the membrane is unaltered in human platelets  
treated with bortezomib (A).  Platelet llb3 integrin activation as measured by 












































































Figure 4.5.  Bortezomib inhibits the proteasome in human platelets but 
does not alter platelet spreading.  Bortezomib and MG132 inhibit the 
proteasome in human platelets (A).  Proteasomal inhibition causes a build 
up of ubiquitinylated proteins in human platelets (B).  Neither bortezomib 
nor MG132 alter platelet spreading on fibrinogen (C). a.u.= arbitrary units. 
Staining + Phalloidin and WGA 
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          To study the effects of bortezomib on megakaryocytes, we developed a 
system to culture human megakaryocytes in vitro.  CD34+ hematopoietic stem cells 
were isolated from human fetal umbilical cord blood and differentiated into 
megakaryocytes using a cytokine cocktail of interleukin 3 (IL-3), stem cell factor 
(SCF), and thrombopoietin (TPO).  These cells have been shown to undergo 
thrombopoiesis over the course of 11-13 days, including the formation of proplatelets 
and the release of platelet-like particles when exposed to a fibrinogen matrix19.  
These CD34+-derived megakaryocytes possess all the necessary components of the 
ubiquitin-proteasome pathway, and proteasomal activity can be blocked in these 
cells using bortezomib or the proteasome inhibitor MG-132 (Figure 4.6a).  We 
assayed the effects of bortezomib on end stage thrombopoiesis in CD34+-
megakaryocytes. Megakaryocytes plated on fibrinogen and exposed to DMSO 
control for 6-12 hours formed proplatelet extensions, just like untreated 
megakaryocytes (Figure 4.6b,c).  In stark contrast, megakaryocytes plated on 
fibrinogen and treated with bortezomib failed to produce proplatelets, and instead 
appeared fully spread (Figure 4.6d).  To ensure the phenotype was specific to 
inhibition of the proteasome, we also treated megakaryocytes with two other 
proteasome inhibitors, MG-132 and lactacystin.  Both proteasome inhibitors 
phenocopied the megakaryocyte spreading seen with bortezomib, confirming that 
this phenotype is a result of proteasomal inhibition (Figure 4.6e,f). 
Because we observed this phenotype when terminal thrombopoiesis was 
occurring on fibrinogen, we next asked if bortezomib-induced megakaryocyte 









































































fibrinogen.  We plated megakaryocytes on fibrinogen, fibronectin, collagen, laminin 
and poly-L-lysine.  Both bortezomib and MG-132 induced megakaryocyte spreading 
on all matrices; however, these effects were most prominent and only statistically 
significant on fibrinogen and fibronectin, both of which are bound by llb3 (Figure 
4.7a).   
llb3 integrin is the most prominent integrin combination expressed on 
megakaryocytes and platelets, and increased expression and/or activation due to 
decreased proteasomal activity could explain the megakaryocytes spreading 
phenotype. To determine whether llb3 integrin function was upregulated, we 
measured the expression of llb integrin by western blot.  Megakaryocytes treated 
with bortezomib did not have increased expression of llb integrin (Figure 4.7b).  
Flow cytometric studies also showed that there was no increased expression of llb 
or 3 integrin on the surface of megakaryocytes (data not shown). These data are 
congruent with published reports demonstrating that while the proteasome regulates 
destruction of pro-llb integrin, it does not regulate llb3 integrin expression14.  Next 
we sought to determine if llb3 had increased activation after bortezomib treatment.  
We measured the binding of megakaryocytes to Pac1, an antibody that binds only to 
activated llb3, and to soluble fibrinogen.  There was no difference in binding to 
either Pac1 or soluble fibrinogen between bortezomib and DMSO-treated 
megakaryocytes, indicating that the mechanism for bortezomib-induced 
megakaryocyte spreading is not due to increased expression or activation of llb3 














































Figure 4.7.  Proteasome inhibited megakaryocytes spread more on fibrinogen but 
do not have elevated CD41 or hyperactive llb3 integrin.  Megakaryocyte 
spreading on various indicated matrices (A).  Megakaryocyte expression of CD41 
as assayed by Western blot (B). Megakaryocyte llb3 integrin activation as 
assayed by Pac1 binding (C).  Soluble fibrinogen binding to megakaryocytes 

































The drastic spreading phenotype of megakaryocytes treated with proteasome 
inhibitors is strikingly reminiscent of the spreading of activated endothelial cells or 
platelets.  In both cases, the small GTPase RhoA activation is necessary for 
spreading20.  We found that RhoA expression was increased in megakaryocytes 
treated with bortezomib, consistent with other proteasomally inhibited cells (Figure 
4.8a)21-23.  Additionally, we found that RhoA was also activated to a greater extent in 
megakaryocytes treated with bortezomib (Figure 4.8b). 
Inactivation of RhoA has been shown to be required for the production of 
proplatelets, and the combination of increased expression and hyperactivation of 
RhoA in proteasome-inhibited megakaryoctyes suggests that RhoA activity may be 
responsible for megakaryocyte spreading and failure to produce proplatelets20.  
Inhibition of RhoA (using C3 transferase) or its downstream kinase ROCK (using Y-
27632) were both able to inhibit bortezomib-induced megakaryocyte spreading, 
though the ROCK inhibitor was much more potent than the RhoA inhibitor (Figure 
4.9a).  Furthermore, the ROCK inhibitor rescued the proplatelet production function 
of bortezomib-treated megakaryocytes (Figure 4.9b).  These data demonstrate that 
enhanced RhoA signaling is responsible for bortezomib-induced failure of proplatelet 




 Thrombocytopenia is a common adverse effect of many chemotherapeutic 





























Figure 4.8.  RhoA is elevated in bortezomib-treated megakaryocytes.  Graphic 
representation of densitometry of western blots for RhoA in DMSO and 
bortezomib treated megakaryocytes (A).  RhoA-GTP pull down on 























































Figure 4.9.  Inhibition of the RhoA signaling pathway restores the ability of CD34+ 
megakaryocytes to form proplatelets.  Graph demonstrating Inhibition of RhoA 
(using C3 Transferase) or ROCK (using Y27632) inhibits megakaryocyte 
spreading and restores production of proplatelets (A).  Megakaryocytes treated 
with-from top to bottom-DMSO, bortezomib or bortezomib + Y27632 (B). 
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refractory multiple myeloma, thrombocytopenia is dose-limiting and the most 
common reason that patients are withdrawn from life-saving treatment8,9.   Most 
chemotherapy-induced thrombocytopenias are a direct result of cytotoxicity to 
hematopoietic stem cells.  However, the kinetics of bortezomib-induced 
thrombocytopenia suggest an alternate mechanism, most likely linked to proplatelet 
budding7.  We have demonstrated that bortezomib-induced thrombocytopenia is due 
to decreased platelet production, not increased platelet destruction.  We have also 
shown that proteasomal inhibition has no effect on the activation state of circulating 
platelets.  Until now, the mechanism of bortezomib-induced thrombocytopenia has 
been unknown.  It has been hypothesized that bortezomib-induced 
thrombocytopenia is a result of diminished NF-B-dependent transcription through 
decreased proteasomal destruction of the inhibitor of NF-B (I-B), which binds to 
and inhibits NF-B7.  The evidence for this hypothesis, however, is lacking; while 
megakaryocytes and platelets posses NF-B, there has been no evidence that NF-
B is required for proplatelet development24.  Moreover, inhibitors of NF-B cause 
platelet and megakaryocyte collapse while proteasomal inhibitors have no effect on 
platelets and causes megakaryocytes to spread25 (Figures 4.3c,4.4d-f).  Though 
there is good evidence to suggest that bortezomib may function as a 
chemotherapeutic through inhibiting NF-B function in tumor cells26, these results do 
not necessarily translate to bortezomib function in megakaryocytes. 
Here we show that bortezomib inhibits proplatelet production from 
megakaryocytes in vitro and that this inhibition results in megakaryocyte spreading 
similar to thrombin treatment of megakaryocytes or platelets. Others have witnessed 
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a similar megakaryocyte spreading phenotype in the presence of constitutively 
active RhoA20.  We show that proteasomally inhibited megakaryocytes have 
elevated levels of RhoA and that a higher proportion of RhoA is in the active, GTP-
bound form.  GTP-RhoA is rapidly targeted for the proteasome via its E3 Ubiquitin 
ligase Smurf1 and deficiency of Smurf1 leads to a buildup of GTP-RhoA and 
subsequent activation of ROCK and downstream signaling21.  This could explain the 
buildup of RhoA and more specifically GTP-RhoA in megakaryocytes treated with 
proteasome inhibitors.  We used inhibitors for both RhoA and ROCK to rescue 
bortezomib-induced megakaryocyte spreading.  Interestingly, inhibition of ROCK and 
to some extent, inhibition of RhoA not only prevented bortezomib treated 
megakaryocytes from spreading but also restored their ability to produce 
proplatelets.  These data strongly suggest that the megakaryocyte phenotype 
caused by proteasomal inhibition is mediated by enhanced RhoA signaling.   
These studies offer the first real insight into the requirement of the 
proteasome for thrombopoiesis. In addition to this work, it is known that Cyclin B is 
proteasomally regulated, and that rapid degradation of Cyclin B is involved in 
megakaryocyte endomitosis27, but it would also be of interest to know the function of 
the proteasome in other aspects of thrombopoiesis including granule trafficking and 
platelet release.  Proteasome inhibitors are under investigation for a multitude of 
malignant disorders and their use as chemotherapeutics is likely to rise drastically in 
the near future.  Because of this it will be important to understand the mechanisms 
of proteasome inhibitor-induced thrombocytopenias in hopes of preventing these 
thrombocytopenias in order to maximize chemotherapeutic effects. 
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Future studies in this field would involve finding a suitable Rho pathway 
inhibitor that could be used as an adjunct to bortezomib therapy.  RhoA is known to 
function at the cell membrane and requires a geranylgeranyl lipid modification to 
localize to the cell membrane.  This lipid is a byproduct of cholesterol synthesis, 
therefore suggesting that statin drugs may be a potential candidate for rescuring 
bortezomib-induced thrombocytopenia.  Statins are especially attractive because 
they are an already approved drug and are among the best-tolerated drugs in all of 
pharmacopeia.  Clearly, the ability of statins to inhibit megakaryocyte spreading and 
restore proplatelet formation in the face of proteasomal inhibition would first have to 
be tested in vitro before moving on to animal or human trials.  
 
Methods 
Human platelet isolation.  Human blood was drawn into acid-citrate-dextrose 
(ACD) (7 ml ACD/42 ml of blood) and was centrifuged (200g for 20 minutes) to 
obtain platelet-rich plasma (PRP). PRP was recentrifuged (500g for 20 minutes) in 
the presence of 100 nM PGE-1. The supernatant was discarded and 50 ml of 
Pipes/saline/glucose (PSG; 5 mM Pipes, 145 mM NaCl, 4 mM KCl, 50mM Na2HPO4, 
1 mM MgCl2–6 H2O, and 5.5 mM glucose), containing 100 nM of PGE-1, was used 
to resuspend the platelet pellet. The platelet suspension was centrifuged (500 g for 
20 minutes), the supernatant was discarded, and the platelet pellet was 
resuspended in Ca2+- and Mg2+-free HBSS. All studies are approved by the 
University of Utah's Institutional Review Board (IRB). The cells were resuspended in 
medium 199 (M199) at 37°C for each experiment.  
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Mouse platelet isolation.  Mouse blood was drawn via carotid artery cannula 
into ACD (150μl/1ml blood)  Blood/ACD was then diluted 1:2 with PSG and 
centerfuged (200g for 10 minutes) to obtain PRP. PRP diluted again 1:2 with PSG 
and was recentrifuged (500g for 7 minutes) in the presence of 100 nM PGE-1. The 
supernatant was discarded and 2 ml of PSG containing 100 nM of PGE-1, was used 
to resuspend the platelet pellet. The platelet suspension was centrifuged (500 g for 7 
minutes), the supernatant was discarded, and the platelet pellet was resuspended in 
Ca2+- and Mg2+-free HBSS. 
Differentiation of CD34+ hematopoietic stem cells.  Umbilical cord blood 
samples from normal full-term human newborns were obtained after informed 
consent by the mothers (IRB# 11919).  Whole blood was diluted in half with 0.9% 
saline and placed on Ficoll-PaqueTM PLUS (Amersham Biosciences, Uppsal, 
Sweden) to separate the mononuclear cells by centrifugation.  Hematopoietic 
progenitors were purified from the mononuclear interphase with magnetic beads that 
were directly conjugated to anti-CD34+ (Miltenyi Biotec Inc., Auburn, CA).  After a 
30-minute incubation period, CD34+ cells were isolated from the mononuclear 
suspension using an Auto-MACS cell separator (Miltenyi).  
 The CD34+ cells were resuspended in 2.5 mls of X Vivo-20 culture medium 
(BioWhittaker, Walkersville, MD) that contained 50 ng/ml of thrombopoietin 
(Chemicon International, Inc., Temecula, CA), 40 ng/ml of human stem cell factor 
(Biosource, Camarillo, CA), and 10 ng/ml of interleukin-3 (IL-3; R&D systems, 
Minneapolis, MN).  The cell suspension was transferred to bacterial tissue culture 
plates to prevent adherence.  The liquid cultures were maintained at 37oC in a 
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humidified 5% CO2 atmosphere and the cells were replenished with fresh growth 
factors and culture medium every 2-3 days.  IL-3 was removed from the culture 
medium on day 7.  At day 13, the cells were placed on immobilized human 
fibrinogen (100 mg/ml;Calbiochem-Novabiochem Corporation, San Diego, CA) 
coated surfaces to generate megakaryocytes that possess proplatelet extensions. 
Mouse studies.  C57BL/6 mice were injected I.V. on Day 0 with 0.1ug/g body 
weight Dylight 488 mouse platelet labeling antibody (Emfret Analytics)  and 2ug/g 
body weight bortezomib in 100ul 10% DMSO in 0.9% saline or DMSO control.  30μL 
blood samples were then taken via tail stick,  each day for the remainder of the 
experiment.  5μL whole blood was added to 44ul HBSS and 1μL phycoerythrin 
conjugated anti-mouse CD41 antibody (BD Biosciences) and taken for analysis 
using a FacScan (Becton Dickinson, Franklin Lakes, NJ).  The remainder of the 
whole blood sample was subjected to complete blood count and differential using a 
Hevavet 950 (Drew Scientific, Waterbury, CT).   
Platelet adhesion and spreading.  8 well borocilicate chamber slides (Nalge 
Nunc International, Rochester, NY) were coated with 100ug/ml fibrinogen, 50μg/ml 
collagen, or 50μg/ml laminin overnight at 4° followed by blocking with 0.5% human 
serum albumin for 30 minutes at 37°.  Chamber slides were washed 3x with HBSS.  
Platelets (2 x 107) in M199 were placed on the coated chamber slides for 30 minutes 
at 37°, 5% CO2 in the presence or absence of 0.05U/ml Thrombin or 20μg/ml ADP. 
Platelets were fixed for 20 minutes with 2% PFA and washed three times with 
HBSS.  Morphologic study of adhered platelets was performed by staining platelets 
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with Alexa 488-phaloidin and 544-WGA followed by imaging using confocal 
microscopy. Platelets were then allowed to spread for 30 minutes. 
Immunocytochemistry.  Cells were fixed with 4% paraformaldehyde for 20 
minutes at room temperature followed by permiabilization in 0.1% Triton-X 100 for 5 
minutes.  Fixed and permiabilized cells were  stained with alexa fluor 488 Phaloidin 
and Alexa fluor 555 wheat germ agglutinin (WGA) and To-pro-3 iodide  (all 
Molecular Probes, Eugene, OR).  Cells wee imaged using an FV300 Olympus IX81 
microscope (Melville, NY). 
Activation of IIb 3 by various agonists.  Activation state of IIb 3 was 
monitored by binding of a ligand-mimetic antibodies. 1 x 106 platelets in M199 were 
treated with agonis concentrations indicated along with FITC-conjugated PAC-1 (BD 
Biosciences, Franklin Lakes, NJ) for human platelets or PE-JonA (Emfret, Eibelstadt, 
Germany) for mouse platelets for 15 minutes at room temperature. Then, platelets 
were analyzed immediately using a FacScan (Becton Dickinson, Franklin Lakes, 
NJ). 
GTPase activation assays.  Activity of RHOA, was measured using activation 
assay kits (Upstate) according to manufacturer’s instructions. Briefly, transfected 
cells were scraped into Mg2+ lysis buffer supplemented with protease inhibitors 
(Roche) and phosphatase inhibitors (Sigma). A small portion of the lysate was 
retained as total cell lysate and the rest was incubated with the assay reagent. GTP-
bound forms were eluted from the assay reagent using Laemmli sample buffer and 
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Platelets play a crucial role in hemostasis and throughout evolution they may 
have been the most important defense against accidental death available in 
mammals.   However, as times change and we are less likely to die of massive 
hemorrhage, and diet and lifestyle changes alter the micro and macro environments 
within our body, platelets take on a different role.  They become the enemy in 
diseases such as thromboembolic disorders, myocardial infarction1, cerebrovascular 
accidents2, atherosclerosis3, arthritis4,5, acute respiratory distress syndrome6 and 
malignancy7.  Because platelets were originally thought to be nothing more than 
cellular fragments that plug up holes in the vascular system, research on these 
fascinating little cells lagged behind much of the rest of biological sciences.  We now 
know that platelets undergo complex cellular processes including translation8, RNA 
splicing9, and division10, in addition to activation in the face of hemorrhage or 
inflammation.  The processes involved in platelet production and activation are 
tightly regulated by cytoskeletal alterations, and modulating these cytoskeletal 
alterations is of keen interest in modulating platelet function or production 
therapeutically.   
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The data presented in this dissertation lend additional insight into these 
cytoskeletal processes and how to study them.  Neural guidance cues (Slits, Netrins, 
Ephrins and Semaphorins) were originally distinguished for their ability to alter the 
migration patterns of axon growth cones, but we now know that these cues also alter 
the migration patterns and activities of the developing vasculature and other systems 
as well.  Because of the highly cytomorphic properties of platelets and the 
similarities in the cytoskeletal changes between platelet, endothelial cell, and axonal 
growth cones, we hypothesized that platelets too may be regulated by the same 
extracellular cues as migrating neurons and endothelial cells.  Indeed, ephrins are 
well known for their ability to stabilize thrombus formation through enhancing 
outside-in platelet integrin signaling11.  Additionally, Semaphorin 4D is also known to 
be elevated in platelet activation, and mice lacking Semaphorin4D have an impaired 
ability to develop stable thrombi12.  However, only one neural guidance cue, 
Semaphorin 3A, has been shown to inhibit platelet cytoskeletal function13, but in the 
wake of my studies, even this knowledge must be called into question.  My result, 
that effects attributed to semaphorin 3E were actually caused by detergent 
contamination, underscores the fragility of platelets but also demonstrates how a 
non-specific molecule such as a detergent can reversibly inhibit platelet cytoskeletal 
rearrangements.  Though these studies did not lead to the next anti-thrombotic 
therapeutic as one might have hoped, they did teach us a great deal about how 
platelets react and more specifically about how to view other potential targets under 
study as anti-thrombotics.  These studies also underscore the necessity for in vivo 
studies and the use of gene-targeted small animal models to demonstrate the 
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specificity of a protein target under question.  Only when these models are used and 
multiple approaches to pathway inhibition have proven successful in vivo can there 
be a start to speculation on the clinical applicability of a candidate anti-platelet 
target. 
After these discoveries, I turned my expertise with platelet function and 
biology towards a different clinical problem; bortezomib, a newly approved 
chemotherapeutic agent used to treat multiple myeloma, results in a dose-limiting 
thrombocytopenia.  Here I show that bortezomib-induced thrombocytopenia is 
caused by aberrant activation of the RhoA GTPase signaling pathway, preventing 
the formation of new platelets from megakaryocytes14.  Though others may have 
possibly come to know this through another route, I was able to make this 
connection because of previous studies in the lab which demonstrated the 
importance of endothelial RhoA signaling in the pathogenesis of cerebral cavernous 
malformations (CCMs)15,16.  The similarities of bortezomib-treated megakaryocytes 
and endothelial cells deficient in CCM2 allowed me to more quickly dissect the 
mechanism by which bortezomib inhibits platelet production in vitro and rescue that 
phenotype with inhibition of RhoA or ROCK.  I now hope to use these findings to 
ameliorate bortezomib-induced thrombocytopenia in vivo, using statins or the ROCK 
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